Brief: Virios Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results
14/03/2023 11:12
March 14 (Reuters) - Virios Therapeutics Inc VIRI.O :
* VIRIOS THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR
2022 FINANCIAL RESULTS
* VIRIOS THERAPEUTICS INC- QTRLY LOSS PER SHARE $0.11
* VIRIOS THERAPEUTICS INC - AS OF DECEMBER 31, 2022, VIRIOS
THERAPEUTICS’ CASH TOTALED $7.0 MILLION
* VIRIOS THERAPEUTICS INC - BELIEVES WILL HAVE SUFFICIENT
RESOURCES TO SUPPORT LONG-COVID EXPLORATORY PROGRAM & FUND
PLANNED OPERATIONS THROUGH MID-2024
Source text for Eikon: ID:nGNXc2wGbr
Further company coverage: VIRI.O
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study